通心络对老年高血压病肾损害患者血清TGF-β1和PDGF的影响

Influence of Tongxinluo on Serum TGF-β1 and PDGF of Elder Patients with Hypertention and Renal Damage

目的:观察通心络对老年高血压病肾损害患者血清TGF-β1和PDGF的影响,初步探讨老年高血压病肾损害的发病机制,为临床上寻找新的疗效观察指标和治疗途径提供一定的试验依据。方法:将符合本研究纳入和排除标准的60例患者随机分为通心络组和安慰剂组各30例。两组均起始接受厄贝沙坦片控制血压达标(130/80 mmHg),达目标血压后通心络组和安慰剂组在原有治疗基础上分别加服通心络胶囊和安慰剂。两组在加服通心络胶囊和安慰剂之前均需测定TGF-β1、PDGF和肾功能指标,其中肾功能指标包括内生肌酐清除率(Ccr)、尿微量白蛋白(UmALB)、尿β2-微球蛋白(Uβ2-MG)。两组加服后持续治疗12周再次检查上述项目。结果:通心络组TGF-β1和PDGF治疗前后组内比较有显著性差异(P<0.05);安慰剂组TGF-β1和PDGF治疗前后组内比较无显著性差异(P>0.05);两组肾功能指标治疗前后组内比较均有显著性差异(P<0.05);两组TGF-β1、PDGF和肾功能指标治疗后组间比较均有显著性差异(P<0.05)。结论:通心络可协同厄贝沙坦进一步改善老年高血压病肾损害患者的肾功能,并且这种作用可能与抑制TGF-β1和PDGF的表达有关。

Objective：To observe the effect of Tongxinluo on serum TGF- 131 and PDGF of elder patients with hypertention and renal damage,preliminarily discuss the mechanism, and find out new marks and therapy. Methods ：60 patients who met inclusive criteria and exclusive criteria were divided into Tongxinluo group and placebo group randomly, each group included 30 patients. All patients initially accepted Irbesartan to control the blood pressure to target value（ 130/80 mmHg） , then Tongxinluo group and placebo group added Tongxinluo capsule and placebo capsule respectively. Before the addition, all patients were examined Ccr, UmALB, uβ1 -MG, TGF --β1 and PDGF. After the addition for 12 weeks, the above examinations were made again. Results：After the addition for 12 weeks, each group had obvious difference in renal function mark（ P 〈 0. 05 ）with preafter comparison method. In the same way Tongxinluo group had obvious difference in TGF- -β1 and PDGF（P 〈 0. 05） ,but placebo group did not have. There was obvious difference in renal function mark, TGF- -β1and PDGF between two groups（P 〈0. 05）. Conclusion： Tongxinluo can cooperate lrbesartan to furtherly im- prove renal function of elder patients with hypertension and renal damage, moreover this effect may be related to inhibiting the expressions of TGF - -β1 and PDGF.